

<b>Reference:</b>	FOI.16159.24
<b>Subject:</b>	Atherosclerotic Cardiovascular Disease and Lipoprotein(a) testing
<b>Date of Request:</b>	6 December 2024

**Requested:**

Please find below a freedom of information request relating to management of patients with ASCVD and Lipoprotein(a) testing.

<b>Question 1:</b> Does Hywel Dda University Health Board have any guidelines/policies for the treatment and management of patients who have peripheral arterial disease (PAD) or have experienced a myocardial infarction ( MI) or stroke?	Yes/No
	If Yes, please provide a copy.

<b>Question 2:</b> Does Hywel Dda University Health Board have any guidelines or policies for testing Lipoprotein (a) (LP(a)) level in patients who have experienced peripheral arterial disease (PAD) or have experienced a myocardial infarction ( MI) or stroke?	Yes/No
	If Yes, please provide a copy.

<b>Question 3:</b> Does Hywel Dda University Health Board have any guidelines or policies for testing Lipoprotein (a) (LP(a)) level in patients who require cardiac rehabilitation?	Yes/No
	If Yes, please provide a copy.

**Response:**

1. Hywel Dda University Health Board (UHB) has provided a copy of its Initial Management of Acute Coronary Syndrome Guideline at Attachment 1. For Secondary prevention, the service uses the relevant NICE Guideline.
2. The UHB does not have any guidelines or policies for testing Lipoprotein (a) (LP(a)) level in patients who have experienced peripheral arterial disease (PAD) or have experienced a myocardial infarction (MI) or stroke.
3. The UHB does not have any guidelines or policies for testing Lipoprotein (a) (LP(a)) level in patients who require cardiac rehabilitation.